Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

NCT04988386 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

389

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloid Cardiomyopathy, Transthyretin-Related

Interventions

DRUG: Acoramidis (AG10)

Sponsor

Eidos Therapeutics, a BridgeBio company